285 related articles for article (PubMed ID: 37373091)
1. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
[TBL] [Abstract][Full Text] [Related]
2. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
3. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulatory functions of VISTA.
Nowak EC; Lines JL; Varn FS; Deng J; Sarde A; Mabaera R; Kuta A; Le Mercier I; Cheng C; Noelle RJ
Immunol Rev; 2017 Mar; 276(1):66-79. PubMed ID: 28258694
[TBL] [Abstract][Full Text] [Related]
5. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
6. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
7. VISTA Regulates the Development of Protective Antitumor Immunity.
Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
[TBL] [Abstract][Full Text] [Related]
8. VISTA expression and patient selection for immune-based anticancer therapy.
Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
[TBL] [Abstract][Full Text] [Related]
9. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
10. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature.
Ren R; Chang X; Chen C; Yu H; Han L
Open Med (Wars); 2023; 18(1):20230866. PubMed ID: 38152334
[TBL] [Abstract][Full Text] [Related]
11. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
[TBL] [Abstract][Full Text] [Related]
13. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
Lines JL; Sempere LF; Broughton T; Wang L; Noelle R
Cancer Immunol Res; 2014 Jun; 2(6):510-7. PubMed ID: 24894088
[TBL] [Abstract][Full Text] [Related]
14. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
[TBL] [Abstract][Full Text] [Related]
15. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
16. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
[TBL] [Abstract][Full Text] [Related]
17. FOXD3 Regulates VISTA Expression in Melanoma.
Rosenbaum SR; Knecht M; Mollaee M; Zhong Z; Erkes DA; McCue PA; Chervoneva I; Berger AC; Lo JA; Fisher DE; Gershenwald JE; Davies MA; Purwin TJ; Aplin AE
Cell Rep; 2020 Jan; 30(2):510-524.e6. PubMed ID: 31940493
[TBL] [Abstract][Full Text] [Related]
18. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
[TBL] [Abstract][Full Text] [Related]
19. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Ferencz B; Török K; Pipek O; Fillinger J; Csende K; Lantos A; Černeková R; Mitták M; Škarda J; Delongová P; Megyesfalvi E; Schelch K; Lang C; Solta A; Boettiger K; Brcic L; Lindenmann J; Rényi-Vámos F; Aigner C; Berta J; Megyesfalvi Z; Döme B
Cancer Immunol Immunother; 2024 May; 73(6):114. PubMed ID: 38693435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
